anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

235,261-235,290 of 319,975

filter-aware
01
Slide 1
MindMed | Investor Presentation Deck | 42 slidesMindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations 1 hit
02
MindMed | Investor Presentation Deck | 42 slidesMindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations 1 hit
03
The slide uses a hub-and-spoke diagram to centralize the company brand around five key strategic pillars.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Loop · Golden Circle1 hit
04
The slide combines team headshots with a list of pharmaceutical products they have worked on and a list of previous company affiliations.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Loop · Golden Circle1 hit
05
The chart uses a Gantt-style visualization to represent clinical trial progress.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · RoadmapLoop · Golden Circle1 hit
06
The slide uses a horizontal timeline format to track clinical trial milestones.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · RoadmapLoop · Golden Circle1 hit
07
MindMed | Investor Presentation Deck | 42 slidesMindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Loop · Golden Circle1 hit
08
MindMed | Investor Presentation Deck | 42 slidesMindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Loop · Golden Circle1 hit
09
The slide uses a 3x2 matrix structure to contrast clinical efficacy, market opportunity, and current treatment limitations.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
10
Uses a process-flow diagram to illustrate biological mechanism.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
Shows specific trial names (Voyage, Panorama, Emerge), sample sizes, randomization, and study phases.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Loop · Golden Circle1 hit
12
The slide uses a structured list format to map specific clinical challenges to mitigation strategies.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Loop · Golden Circle1 hit
13
The slide uses a timeline framework to illustrate the stacking of IP protections over time.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Loop · Golden Circle1 hit
14
MindMed | Investor Presentation Deck | 42 slidesMindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Loop · Golden Circle1 hit
15
The slide outlines the clinical development strategy for a drug candidate, emphasizing continuity from Phase 2b to Phase 3.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Loop · Golden Circle1 hit
16
The slide uses a bar chart to compare effect sizes (Cohen's d) across four treatment categories.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
17
The slide uses a list-based framework to map clinical outcomes to target product profile attributes.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
18
The slide outlines two distinct study protocols with specific sample sizes and dosing regimens, including a primary endpoint at week 12.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
19
Includes study timeline, randomization, entry criteria, and endpoints.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
20
Shows a process flow between follow-up observation and potential treatment based on clinical criteria.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
21
Includes logos for Voyage and Panorama studies; references statistical power assumptions in footnotes.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
22
MindMed | Investor Presentation Deck | 42 slidesMindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
23
The slide uses a table to establish scientific credibility for the company's therapeutic focus.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
24
The chart displays LS Mean Change from baseline across multiple dose groups (25, 50, 100, 200 ug) versus placebo.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
25
The slide outlines a clinical trial protocol with a primary endpoint at week 6 and a 40-week extension phase.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
26
Includes study timeline, randomization details, entry criteria, and secondary endpoints.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
27
The slide features the MindMed logo and the specific drug candidate and trial phase.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
125
Talabat | Investor Event Presentation Deck | 127 slidesTalabat | Investor Event Presentation Deck | 127 slides · Talabat
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
126
Talabat | Investor Event Presentation Deck | 127 slidesTalabat | Investor Event Presentation Deck | 127 slides · Talabat
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
127
Talabat | Investor Event Presentation Deck | 127 slidesTalabat | Investor Event Presentation Deck | 127 slides · Talabat
Conference presentation Investor relations Beat · Ultimate Achievement1 hit